References
- Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998; 16(2): 168-71.
- Wells JM, Li LH, Sen A, Jahreis GP, Hui SW. Electroporation-enhanced gene delivery in mammary tumors. Gene Ther 2000; 7(7): 541-7.
- Bettan M, Ivanov MA, Mir LM, Boissiere F, Delaere P, Scherman D. Efficient DNA electrotransfer into tumors. Bioelectrochemistry 2000; 52(1): 83-90.
- Cemazar M, Sersa G, Wilson J, Tozer GM, Hart SL, Grosel A et al. Effective gene transfer to solid tumors using different nonviral gene delivery techniques: electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther 2002; 9(4): 399-406.
- Cemazar M, Wilson I, Dachs GU, Tozer GM, Sersa G. Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy - spatial and time dependent distribution. BMC Cancer 2004; 4(81.)
- Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2005; 12(3): 217-27.
- Scherer L, Rossi JJ. Recent applications of RNAi in mammalian systems. Curr Pharm Biotechnol 2004; 5(4): 355-60.
- Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13(6): 464-77.
- Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006; 13(6): 541-52.
- McAnuff MA, Rettig GR, Rice KG. Potency of siRNA versus shRNA mediated knockdown in vivo. J Pharm Sci 2007; 96(11): 2922-30.
- Gottesman MM. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther 2003; 10(7): 501-8.
- Meyer M, Wagner E. Recent developments in the application of plasmid DNA-based vectors and small interfering RNA therapeutics for cancer. Hum Gene Ther 2006; 17(11): 1062-76.
- Grassi G, Maccaroni P, Meyer R, Kaiser H, D'Ambrosio E, Pascale E et al. Inhibitors of DNA methylation and histone deacetylation activate cytomegalovirus promoter-controlled reporter gene expression in human glioblastoma cell line U87. Carcinogenesis 2003; 24(10): 1625-35.
- Krishnan M, Park JM, Cao F, Wang D, Paulmurugan R, Tseng JR et al. Effects of epigenetic modulation on reporter gene expression: implications for stem cell imaging. FASEB J 2006; 20(1): 106-8.
- Liu HS, Jan MS, Chou CK, Chen PH, Ke NJ. Is green fluorescent protein toxic to the living cells? Biochem Biophys Res Commun 1999; 260(3): 712-7.
- Jana S, Chakraborty C, Nandi S, Deb JK. RNA interference: potential therapeutic targets. Appl Microbiol Biotechnol 2004; 65(6): 649-57.
- Bantounas I, Phylactou LA, Uney JB. RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 2004; 33(3): 545-57.
- Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther 2006; 13(4): 644-70.
- Birmingham A, Anderson E, Sullivan K, Reynolds A, Boese Q, Leake D et al. A protocol for designing siRNAs with high functionality and specificity. Nat Protoc 2007; 2(9): 2068-78.
- Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16(8): 948-58.
- Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296(5567): 550-3.
- Cullen BR. Induction of stable RNA interference in mammalian cells. Gene Ther 2006; 13(6): 503-8.
- McManus MT, Petersen CP, Haines BB, Chen J, Sharp PA. Gene silencing using micro-RNA designed hairpins. RNA 2002; 8(6): 842-50.
- Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006; 11(1-2): 67-73.
- Russ V, Wagner E. Cell and tissue targeting of nucleic acids for cancer gene therapy. Pharm Res 2007; 24(6): 1047-57.
- Sersa G, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy of tumours. Radiol Oncol 2006; 40(3): 163-74.
- Heller LC, Heller R. In vivo electroporation for gene therapy. Hum Gene Ther 2006; 17(9): 890-7.
- Tamura T, Sakata T. Application of in vivo electroporation to cancer gene therapy. Curr Gene Ther 2003; 3(1): 59-64.
- Cemazar M, Sersa G. Electrotransfer of therapeutic molecules into tissues. Curr Opin Mol Ther 2007; 9(6): 554-62.
- Fan Y, Xin XY, Chen BL, Ma X. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo. Pathology 2006; 38(6): 561-7.
- Nakai N, Kishida T, Shin-Ya M, Imanishi J, Ueda Y, Kishimoto S et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 2007; 14(4): 357-65.
- Takei Y, Nemoto T, Mu P, Fujishima T, Ishimoto T, Hayakawa Y et al. In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 2008; 7(1): 211-21.
- Golzio M, Mazzolini L, Ledoux A, Paganin A, Izard M, Hellaudais L et al. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther 2007; 14(9): 752-9.
- Takahashi Y, Nishikawa M, Kobayashi N, Takakura Y. Gene silencing in primary and metastatic tumors by small interfering RNA delivery in mice: quantitative analysis using melanoma cells expressing firefly and sea pansy luciferases. J Control Release 2005; 105(3): 332-43.
- Takahashi Y, Nishikawa M, Takakura Y. Suppression of tumor growth by intratumoral injection of short hairpin RNA-expressing plasmid DNA targeting beta-catenin or hypoxia-inducible factor 1alpha. J Control Release 2006; 116(1): 90-5.
- Rejiba S, Wack S, Aprahamian M, Hajri A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007; 98(7): 1128-36.
- Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002; 10(3): 549-61.
- Devi GR. siRNA-based approaches in cancer therapy. Cancer Gene Ther 2006; 13(9): 819-29.
- Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klibanov AM. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci U S A 2005; 102(16): 5679-84.
- Grayson AC, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006; 23(8): 1868-76.
- Merkerova M, Klamova H, Brdicka R, Bruchova H. Targeting of gene expression by siRNA in CML primary cells. Mol Biol Rep 2007; 34(1): 27-33.
- Bartlett DW, Davis ME. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006; 34(1): 322-33.
- Corish P, Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian cells. Protein Eng 1999; 12(12): 1035-40.
- Agami R. RNAi and related mechanisms and their potential use for therapy. Curr Opin Chem Biol 2002; 6(6): 829-34.
- Caplen NJ. Gene therapy progress and prospects. Downregulating gene expression: the impact of RNA interference. Gene Ther 2004; 11(16): 1241-8.
- Ryther RC, Flynt AS, Phillips JA, III, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005; 12(1): 5-11.